Lupin Receives Great Place To Work Certification for 2026-27
Filing Summary
Lupin Limited has been awarded the Great Place To Work® certification for 2026-27. This recognition is based on a global study involving all subsidiaries and geographies, with an 85% employee participation rate. Lupin, a global pharmaceutical leader, employs over 24,000 professionals and invested INR 40 billion in employee benefits in FY25. The certification highlights Lupin’s commitment to an inclusive workplace culture. The company specializes in pharmaceutical products, including branded and generic formulations, and operates 15 manufacturing sites and 7 research centers globally.
Lupin Limited has announced its receipt of the Great Place To Work® certification for the period 2026-27. This certification is recognized as a standard for workplace excellence and was achieved through a global study encompassing all of Lupin’s subsidiaries and geographies. The study recorded an 85% participation rate from Lupin employees.
The certification reflects the involvement of Lupin’s workforce, which consists of over 24,000 professionals across various functions and geographies. In the fiscal year 2025, Lupin invested INR 40 billion in employee benefits and dedicated 1,253,456 hours to employee training. This investment underscores the company’s focus on enhancing employee experience and fostering an inclusive workplace culture.
Yashwant Mahadik, President of Global Human Resources at Lupin, commented on the certification, emphasizing the company’s values-driven workplace culture. He noted that employees across geographies feel respected, valued, and empowered to perform effectively.
Lupin Limited is a global leader in the pharmaceutical industry, headquartered in Mumbai, India. The company distributes its products in over 100 markets and specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin holds a strong market position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health.
Lupin operates 15 state-of-the-art manufacturing sites and 7 research centers globally. The company is committed to improving patient health outcomes through its subsidiaries, which include Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.